| Ytd | -56.69% | |
| 1y | -79.70% |
| Open | 1.70 | Prev Close | 1.67 | Low | 1.67 | High | 1.70 | Mkt Cap | 4.21M |
| Vol | 59.55K | Avg Vol | 108.23K | EPS | -5.16 | P/E | -0.32 | Forward P/E | -0.73 |
| Beta | 1.96 | Short Ratio | 3.31 | Inst. Own | 7.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 2.06 | 200-d Avg | 3.25 | 1yr Est | 13.20 |
IMNN News
Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting
Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 mini
Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMN
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark
On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to ret
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im
U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of benchmark
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.